Amgen Inc. will provide a full refund for the cholesterol-lowering medicine Repatha (evolocumab) if the treatment does not live up to expectations of reducing heart attacks and strokes in a new outcomes-based reimbursement contract with Harvard Pilgrim Health Care.
The companies announced the new outcomes-based reimbursement contract for Repatha, billed as the "first of